Sotera Health upgraded by JP Morgan with a new price target
$SHC
Misc Health and Biotechnology Services
Health Care
JP Morgan upgraded Sotera Health from Underweight to Neutral and set a new price target of $18.00 from $6.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2024 | $13.00 | Neutral | Piper Sandler |
| 4/3/2024 | $18.00 → $16.00 | Neutral → Buy | Citigroup |
| 3/25/2024 | $15.00 → $15.50 | Hold → Buy | Jefferies |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 6/26/2023 | $24.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/23/2023 | $6.00 → $18.00 | Underweight → Neutral | JP Morgan |
| 1/11/2023 | $6.00 → $22.00 | Underweight → Overweight | Barclays |
| 1/11/2023 | $25.00 | Peer Perform → Outperform | Wolfe Research |
Ratings for Sotera Health (NASDAQ:SHC) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 3 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.79, with a high estimate of $20.00 and a low estimate of $13.00. A decline of 2.67% from the prior aver
Piper Sandler analyst Jason Bednar initiates coverage on Sotera Health (NASDAQ:SHC) with a Neutral rating and announces Price Target of $13.
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
WESTPORT, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, today announced the appointment of Kurt Roth as Partner and Head of Healthcare for Compass Group Management LLC. In this role, Roth will work with the organization's senior investment professionals to launch CODI's new healthcare vertical. "Last December, we embarked on a journey to launch our third industry vertical," said Elias Sabo, CEO of Compass Diversified. "We chose healthcare as we believe it has multiple attractive, high-growth sectors with strong barriers to entry and advantageous demographic trends. Finding the right perso
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00
Citigroup upgraded Sotera Health from Neutral to Buy and set a new price target of $16.00 from $18.00 previously
Jefferies upgraded Sotera Health from Hold to Buy and set a new price target of $15.50 from $15.00 previously
8-K - Sotera Health Co (0001822479) (Filer)
10-Q - Sotera Health Co (0001822479) (Filer)
8-K - Sotera Health Co (0001822479) (Filer)
CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions. "The management team is looking forward to the Company's inaugural Investor Day since going public in 2020," said Michael J. Petras, Jr., Chair and CEO. "During the past four years, we have achieved top- and bo
Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,
CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.
Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,
CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.
Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023Successfully refinanced debt structure, extending debt maturities to 2031Reaffirming 2024 outlook CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test